{"id":18012,"title":"#PHARMA: Want to invest in the new Berkshire Hathaway for Health Care?","publisher":"Share Talk","author":"sharetalk","published":"2017-11-28T10:54:02+00:00","modified":"2017-11-28T10:54:02+00:00","canonical_url":"https://www.share-talk.com/pharma-want-to-invest-in-the-new-berkshire-hathaway-for-health-care/","markdown_url":"https://www.share-talk.com/pharma-want-to-invest-in-the-new-berkshire-hathaway-for-health-care.md","json_url":"https://www.share-talk.com/pharma-want-to-invest-in-the-new-berkshire-hathaway-for-health-care.json","category":"Learning and Investing","categories":["Learning and Investing"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1","format":"news","language":"en-GB","content":"Peter Garcia, the CFO at PDL BioPharma explains that in his view, PDL is ‘unique’. Located in Lake Tahoe, Nevada,  PDL is a publicly traded private equity group listed on Nasdaq: #PDLI.\n\n‘PDL allows investors to derisk and invest in a portfolio of products and companies’ says Mr Garcia. ‘We recently bought a company and bought a drug to put into that company. We don’t do research and development ourselves. We acquire income streams’.\n\nPDL BioPharma seeks to provide a significant return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries.\n\nThis interview is one of a series with Edison pharma clients shot at the Biotech and Money Conference at the Waldorf Hotel, London on 14.11.2017."}